[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spasticity-post-stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spasticity-post-stroke":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100650254","spinal-cord-stimulation-for-poststroke-spasticity-100650254",false,"NCT07744659","Spinal Cord Stimulation for Poststroke Spasticity","Spinal Cord Stimulation for Poststroke Spasticity: a Multicentre, Double-blind, Randomised, Sham-controlled Trial (SCS-PSS)","SCS-PSS","Inclusion Criteria:\n\n1. Aged ≥18 years and \\\u003C75 years, regardless of sex;\n2. Diagnosed with ischemic or hemorrhagic stroke, with unilateral or single-limb motor dysfunction persisting for at least 6 months;\n3. The primary brain lesion and its underlying cause are clinically stable;\n4. Presence of unilateral upper- or lower-limb spasticity, with a Modified Ashworth Scale (MAS) grade of ≥2 in at least two muscle groups of the affected limb;\n5. Post-stroke limb dysfunction has not reached the treatment goal despite previous interventions, such as physical therapy and oral medications, and the participant's condition has shown no recent improvement;\n6. The type and dose of existing rehabilitation therapy and oral antispastic medications must remain unchanged during the study;\n7. Willing and able to complete all study visits and procedures;\n8. Able to understand the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Any contraindication to spinal cord stimulation surgery;\n2. Uncontrolled refractory epilepsy;\n3. Presence of tonic spasticity, such as decorticate rigidity or decerebrate rigidity;\n4. Poorly controlled severe psychiatric or cognitive impairment, defined as a Beck Depression Inventory-II score \\>25 or a Mini-Mental State Examination score \\\u003C24;\n5. Active systemic infection;\n6. Presence of an implanted neurostimulator or drug delivery system;\n7. Botulinum toxin treatment within 4 months before enrollment;\n8. Plans to initiate any new treatment during the study that may affect limb movement, including chemical denervation therapies (such as botulinum toxin), oral antispastic medications, surgical procedures (such as peripheral neurotomy or contralateral C7 nerve transfer), or other physical therapy interventions;\n9. Pregnancy, breastfeeding, or planned pregnancy during the study;\n10. The participant or family is unable or unwilling to participate in long-term SCS treatment management;\n11. Participation in another clinical study within 4 weeks before signing informed consent;\n12. Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.","ALL","18 Years","75 Years",{"count":21,"type":22},92,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn whether spinal cord stimulation (SCS) is effective in treating post-stroke spasticity in adults. It will also evaluate the safety of the implanted SCS system. The main questions it aims to answer are:\n\n1. Does active SCS reduce limb spasticity compared with sham stimulation?\n2. What device-related problems do participants experience during the study?\n\nAll participants receive the same implantation and programming procedures,but no therapeutic stimulation(0 mA) for sham SCS group duringthe first 6 weeks after randomization.\n\nParticipants will:\n\n1. Have an SCS system surgically implanted\n2. Be randomly assigned to receive active SCS or sham SCS for 6 weeks\n3. After completion of the 6-week randomized comparison period, active stimulation will be initiated for all participants.\n4. Attend a post-operative visit within 3 to 7 days after surgery for device activation or sham activation, programming, safety checks, and study assessments\n5. Attend follow-up visits for study assessments at approximately 6, 12, 24 weeks, 1 year and 2 years after randomization\n6. Complete assessments of muscle spasticity, joint range of motion, motor function, walking ability, daily functioning, pain, and quality of life\n7. Report any medical problems or device-related problems during the study",[28],"Spasticity Post Stroke",[30,31,32,33,34],"Spinal Cord Stimulation","Spasticity","Limb function","Stroke","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-07-29",{"date":38,"type":39},"2026-08-04","ACTUAL",{"date":41,"type":22},"2026-08-06",{"date":43,"type":22},"2027-05-31",{"name":45,"class":46},"Beijing Pins Medical Co., Ltd","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100646228","extracorporeal-shock-wave-therapy-in-botulinum-toxin-treated-patients-with-post-stroke-ankle-plantar-flexor-spasticity-100646228","NCT07695038","Extracorporeal Shock Wave Therapy in Botulinum Toxin-Treated Patients With Post-Stroke Ankle Plantar Flexor Spasticity","Effectiveness of Extracorporeal Shock Wave Therapy as an Adjunct to Botulinum Toxin Injection in Patients With Post-Stroke Ankle Plantar Flexor Spasticity: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of stroke according to the World Health Organization (WHO) (1989) definition.\n* Stroke diagnosis confirmed by magnetic resonance imaging (MRI).\n* Patients aged between 18 and 65 years.\n* Clinically stable condition after stroke.\n* Patients who have undergone routine Botulinum Toxin Type A (BoNT-A) injection to the gastrocnemius muscle.\n* Presence of ankle plantar flexor spasticity with a Modified Ashworth Scale (MAS) score of greater than or equal to 1 (MAS ≥ 1).\n\nExclusion Criteria:\n\n* Presence of fixed contracture at the ankle joint.\n* History of prior antispastic surgical procedures.\n* Changes in antispastic medication dosage or type within the last 6 months.\n* Active infection or malignancy at the application site.\n* Presence of a cardiac pacemaker.\n* Bleeding disorders or advanced vascular disease.\n* Pregnancy.\n* Presence of neuromuscular junction disease or motor neuron disease.\n* Known allergy or hypersensitivity to Botulinum Toxin Type A.\n* Current use of antibiotics.","65 Years",{"count":57,"type":22},32,[25],"The goal of this clinical trial is to learn if radial Extracorporeal Shock Wave Therapy (rESWT) is effective in reducing ankle plantar flexor spasticity and improving walking functions in stroke patients who have already received Botulinum Toxin type A (BoNT-A) injections. The main questions it aims to answer are:\n\n* Does adding rESWT to standard physical therapy significantly lower muscle spasticity in patients who have received BoNT-A, compared to receiving physical therapy alone after the injection?\n* Does combining rESWT with BoNT-A injection improve functional walking parameters (such as gait speed, cadence, and step length) and daily life independence more than the BoNT-A and physical therapy combination alone?\n* Can rESWT induce additional structural and flexibility improvements in the BoNT-A injected gastrocnemius muscle, as measured objectively by ultrasound imaging and strain elastography?\n\nResearchers will compare a group of participants receiving both rESWT and conventional physical therapy (Group 1) to a comparison group receiving only conventional physical therapy (Group 2) to see if rESWT provides additional clinical benefits. All participants in both groups will have already undergone routine BoNT-A injections one week prior to starting the study treatments.\n\nParticipants will:\n\n* Undergo a 3-week conventional physical therapy and rehabilitation program, consisting of 2 to 3 hours of therapy per day, 5 days a week.\n* Receive 3 weekly sessions of rESWT (2000 pulses per session applied to the calf muscles) if they are randomized into the rESWT group.\n* Attend clinical evaluation visits and objective assessment sessions-including high-tech computerized gait analysis and specialized musculoskeletal ultrasound imaging-before the treatment, at the end of the 3rd week, and at a 12-week follow-up.",[33,61,62,63,64],"Post-stroke Spasticity of the Lower Limb","Post-Stroke Spasticity","Spasticity of the Plantar Flexors","Spasticity, Post-Stroke","2026-07-04",{"date":67,"type":39},"2026-07-10",{"date":69,"type":22},"2026-07-20",{"date":71,"type":22},"2027-08-20",{"name":73,"class":74},"Pamukkale University","OTHER"]